{"id":"tacrolimus-targeted-half-dose","safety":{"commonSideEffects":[{"rate":"20–40%","effect":"Nephrotoxicity / renal impairment"},{"rate":"30–50%","effect":"Hypertension"},{"rate":"10–30%","effect":"Hyperglycemia / new-onset diabetes"},{"rate":"10–25%","effect":"Neurotoxicity (tremor, headache, confusion)"},{"rate":"20–40%","effect":"Infections"},{"rate":"10–20%","effect":"Hyperkalemia"},{"rate":"5–15%","effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12 and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of interleukin-2 and other cytokines essential for T-cell proliferation and differentiation. The 'half-dose' formulation refers to a reduced-dose strategy, likely employed to minimize nephrotoxicity and other adverse effects while maintaining immunosuppressive efficacy in transplant recipients.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the transcription of pro-inflammatory cytokines, thereby reducing immune rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:59.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver transplantation)"},{"name":"Graft-versus-host disease prevention and treatment"}]},"trialDetails":[{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT02446431","phase":"EARLY_PHASE1","title":"Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","status":"RECRUITING","sponsor":"Miller Children's & Women's Hospital Long Beach","startDate":"2014-07","conditions":"Solid Tumor","enrollment":20},{"nctId":"NCT02154854","phase":"PHASE4","title":"Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2013-07","conditions":"De Novo Transplant Disease","enrollment":104},{"nctId":"NCT01744470","phase":"PHASE4","title":"Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-05","conditions":"De Novo Transplant Disease","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf®"],"phase":"marketed","status":"active","brandName":"Tacrolimus targeted half-dose","genericName":"Tacrolimus targeted half-dose","companyName":"University Hospital, Tours","companyId":"university-hospital-tours","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a small molecule inhibitor of the FK506-binding protein 1A, which is involved in the regulation of the immune system. It is used to treat conditions such as solid tumors, hematologic malignancies, delayed graft function, and de novo transplant disease, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}